GlassScriptPhysician profile
Jerry H Singer
NPI 1376545665
$4,021.19
in general payments reported to CMS, 2019-2025
35 companies · $446 in 2025
The $446 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $760 · 2020: $336 · 2021: $659 · 2022: $606 · 2023: $394 · 2024: $820 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,385 · Debt Forgiveness: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,385.13 |
| Debt Forgiveness | $275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $770.20 | 2019-2024 | Aveed, Xiaflex, Edex |
| Astellas Pharma US INC | $661.60 | 2019-2025 | Xtandi |
| Antares Pharma, INC. | $383.00 | 2019-2025 | Xyosted, Nocdurna, Tlando |
| Olympus America INC. | $312.50 | 2019-2024 | |
| Endo USA, INC. | $265.29 | 2024-2025 | Xiaflex, Aveed |
| Ferring Pharmaceuticals INC. | $251.50 | 2019-2024 | Adstiladrin |
| Janssen Biotech, INC. | $126.67 | 2019-2025 | Erleada, Balversa, Akeega |
| Allergan, INC. | $108.68 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $106.49 | 2022-2025 | |
| Myovant Sciences INC. | $93.63 | 2021-2022 | |
| Blue Earth Diagnostics | $79.86 | 2020-2024 | |
| Pfizer INC. | $69.57 | 2023-2024 | |
| Boston Scientific Corporation | $68.77 | 2019-2024 | Moses 550 Dfl |
| Tolmar Pharmaceuticals, INC. | $66.78 | 2021-2022 | |
| Myriad Genetic Laboratories, INC. | $60.23 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $58.35 | 2023-2025 | Eligard, Jatenzo |
| Halozyme INC | $56.34 | 2023 | |
| Aytu Biopharma, INC. | $48.21 | 2019 | |
| Abbvie INC. | $45.42 | 2019-2022 | |
| Clarus Therapeutics INC. | $39.27 | 2021 | |
| Medtronic, INC. | $36.11 | 2022 | |
| Dendreon Pharmaceuticals LLC | $29.96 | 2025 | Provenge |
| Neotract INC. | $28.34 | 2019 | |
| Urogen Pharma, INC. | $27.69 | 2023 | Jelmyto |
| Sumitomo Pharma America, INC. | $27.29 | 2024 | Orgovyx |
| Acerus Pharmaceuticals Corporation | $27.12 | 2022 | |
| Isoray, INC | $26.62 | 2022 | |
| Urovant Sciences INC | $23.14 | 2022 | |
| Rochester Medical Corporation | $21.70 | 2019 | |
| Hologic Sales and Service, LLC | $20.16 | 2022 | |
| Accord Healthcare, INC. | $18.25 | 2023 | |
| Metuchen Pharmaceuticals | $18.09 | 2020 | |
| Advanced Accelerator Applications | $17.62 | 2020 | |
| Avadel Specialty Pharmaceuticals, LLC | $14.01 | 2019 | |
| Laborie Medical Technologies Corp. | $12.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerry Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.